Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × regorafenib × Other hematologic neoplasm × Clear all

Phase

Phase 1 3 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 88 Sarcoma 13 Thoracic 5 Gynecologic 5 CNS 5 Genitourinary 4 Dermatologic 4 Tumor-Agnostic 2 Other solid neoplasm 2 Head & Neck 2 Plasma cell 1 Other hematologic neoplasm 1 Lymphoid 1 Endocrine 1

Conditions

Hematologic Neoplasms 1

Interventions

Cyclophosphamide 361 Cytarabine 297 fludarabine phosphate 200 Rituximab 187 fludarabine 168 Methotrexate 166 Azacitidine 159 venetoclax 153 Busulfan 144 Mycophenolic Acid 124 Whole-Body Irradiation 123 Filgrastim 123 Peripheral Blood Stem Cell Transplantation 119 Etoposide 117 Tacrolimus 113 Vincristine 97 Melphalan 95 Dexamethasone 95 Imatinib Mesylate 86 Cyclosporine 86 Granulocyte Colony-Stimulating Factor 79 Daunorubicin 78 Antilymphocyte Serum 78 Decitabine 77 Radiotherapy 76 Dasatinib 64 Lenalidomide 63 Doxorubicin 63 Idarubicin 59 Prednisone 58

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05159245 2024-07-15

FINPROVE

Helsinki University Central Hospital

Phase 2 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡